Anastrozole Tablet
Product Images NDC 63629-5269

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 63629-5269). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Anastrozole Fig1)

A Kaplan-Meier survival curve chart showing disease-free survival in months for two randomized treatments: anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, while the x-axis shows time in months, up to 96 months. The chart includes the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve chart comparing disease-free survival over 96 months for patients treated with anastrozole versus tamoxifen. The vertical axis shows the proportion alive and disease-free, while the horizontal axis shows disease-free survival in months. Numbers of patients at risk at various time points are listed below the graph for both treatment groups.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier curve chart comparing the proportion of patients remaining event-free over time (months) between two treatments: Anastrozole and Tamoxifen. The x-axis represents time to event in months up to 120 months, and the y-axis shows the proportion event free ranging from 0.50 to 1.00. The chart includes numbers of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve graph depicting hormone event-free proportions over time in months for Anastrozole and Tamoxifen treatments. The x-axis represents time to event up to 120 months, and the y-axis shows the proportion hormone event-free ranging from 0.50 to 1.00. Patient counts at risk are shown below the x-axis for both treatments at multiple time points.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

Kaplan-Meier plot displaying the proportion of patients without disease progression over time (months) comparing two randomized treatments: Anastrozole and Tamoxifen. The y-axis represents the proportion not progressing, and the x-axis indicates time to progression in months, with survival curves for both treatment groups.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A survival curve graph comparing the proportion of progression-free patients over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion not progressing. The graph includes patient risk numbers at various time points.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure diagram of the active ingredient Anastrozole, showing its molecular arrangement including aromatic rings and functional groups represented with standard chemical notation.*

FDA Label Image

Label Image (Lbl636295269)

Label for Anastrozole 1 mg tablet by Bryant Ranch Prepack, showing a white round tablet with imprint 'AHI'. The label indicates a package count of 30 tablets, compares to Arimidex 1 mg tablet by Intas Pharmaceuticals Limited, and includes storage instructions to keep tightly closed and store at 20°-25°C (68°-77°F). The NDC is 63629-5269-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.